BSE:509079

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. More Details


Snowflake Analysis

Mediocre balance sheet with questionable track record.

Share Price & News

How has Gufic Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 509079's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.0%

509079

-5.8%

IN Pharmaceuticals

-4.3%

IN Market


1 Year Return

12.6%

509079

47.7%

IN Pharmaceuticals

-1.6%

IN Market

Return vs Industry: 509079 underperformed the Indian Pharmaceuticals industry which returned 47.7% over the past year.

Return vs Market: 509079 exceeded the Indian Market which returned -1.6% over the past year.


Shareholder returns

509079IndustryMarket
7 Day-2.0%-5.8%-4.3%
30 Day-9.0%-1.0%-4.2%
90 Day2.5%13.6%6.6%
1 Year12.6%12.6%49.6%47.7%0.2%-1.6%
3 Year-1.0%-1.1%31.3%27.7%1.9%-3.0%
5 Year114.4%113.7%0.3%-3.4%38.6%28.4%

Price Volatility Vs. Market

How volatile is Gufic Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Gufic Biosciences undervalued compared to its fair value and its price relative to the market?

51.25x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 509079 (₹80.9) is trading above our estimate of fair value (₹44.93)

Significantly Below Fair Value: 509079 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 509079 is poor value based on its PE Ratio (51.2x) compared to the IN Pharmaceuticals industry average (21.4x).

PE vs Market: 509079 is poor value based on its PE Ratio (51.2x) compared to the Indian market (15.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 509079's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 509079 is overvalued based on its PB Ratio (6.5x) compared to the IN Pharmaceuticals industry average (2.1x).


Next Steps

Future Growth

How is Gufic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gufic Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Gufic Biosciences performed over the past 5 years?

26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 509079 has high quality earnings.

Growing Profit Margin: 509079's current net profit margins (3.8%) are lower than last year (6.8%).


Past Earnings Growth Analysis

Earnings Trend: 509079's earnings have grown significantly by 26.1% per year over the past 5 years.

Accelerating Growth: 509079's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 509079 had negative earnings growth (-50.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 509079's Return on Equity (12.8%) is considered low.


Next Steps

Financial Health

How is Gufic Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 509079's short term assets (₹2.6B) exceed its short term liabilities (₹2.2B).

Long Term Liabilities: 509079's short term assets (₹2.6B) exceed its long term liabilities (₹358.2M).


Debt to Equity History and Analysis

Debt Level: 509079's debt to equity ratio (112%) is considered high.

Reducing Debt: 509079's debt to equity ratio has increased from 108.8% to 112% over the past 5 years.

Debt Coverage: 509079's debt is well covered by operating cash flow (42.6%).

Interest Coverage: 509079's interest payments on its debt are not well covered by EBIT (1.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Gufic Biosciences's current dividend yield, its reliability and sustainability?

0.061%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 509079's dividend (0.061%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.58%).

High Dividend: 509079's dividend (0.061%) is low compared to the top 25% of dividend payers in the Indian market (2.32%).


Stability and Growth of Payments

Stable Dividend: 509079 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 509079 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 509079 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 509079's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Pranav Choksi (37 yo)

no data

Tenure

₹2,355,175

Compensation

Mr. Pranav Jayesh Choksi has been an Executive Whole Time Director of Gufic Biosciences Ltd. since June 25, 2004 and serves as its Chief Executive Officer. Mr. Choksi serves as Chief Executive Officer & Wh ...


CEO Compensation Analysis

Compensation vs Market: Pranav's total compensation ($USD31.98K) is below average for companies of similar size in the Indian market ($USD48.88K).

Compensation vs Earnings: Pranav's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jayesh Choksi
Chairman & MDno data₹4.00m23.66%
₹ 1.5b
Pranav Choksi
CEO & Whole Time Directorno data₹2.36m9.34%
₹ 588.0m
Devkinandan Roonghta
Chief Financial Officer1.92yrs₹1.76mno data
Ami Shah
Company Secretary4.33yrs₹696.61kno data
Pankaj Gandhi
Whole-Time Director7.08yrs₹936.33kno data
Hemal Desai
Whole-Time Director5.83yrs₹903.92k0.000010%
₹ 629.6
Debesh Das
Vice-President of Ethical Sales & Marketing5.58yrs₹4.42mno data

4.3yrs

Average Tenure

55yo

Average Age

Experienced Management: 509079's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jayesh Choksi
Chairman & MDno data₹4.00m23.66%
₹ 1.5b
Pranav Choksi
CEO & Whole Time Directorno data₹2.36m9.34%
₹ 588.0m
Pankaj Gandhi
Whole-Time Director7.08yrs₹936.33kno data
Hemal Desai
Whole-Time Director5.83yrs₹903.92k0.000010%
₹ 629.6
Shreyas Patel
Non Executive Independent Director6.08yrs₹40.00k0.0033%
₹ 210.3k
Gopal Daptari
Independent Director3.83yrs₹15.00kno data
Shrirang Vaidya
Independent Director2.58yrs₹45.00kno data
Balram Singh
Non-Executive & Non Independent Director2.33yrsno datano data
Rabi Sahoo
Non-Executive Independent Director1.25yrsno datano data
Anu Aurora
Independent Director0.67yrno datano data

3.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 509079's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Gufic Biosciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gufic Biosciences Limited
  • Ticker: 509079
  • Exchange: BSE
  • Founded: 1970
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹6.296b
  • Shares outstanding: 77.83m
  • Website: https://gufic.com

Number of Employees


Location

  • Gufic Biosciences Limited
  • SM House
  • 1st to 4th Floor
  • Mumbai
  • Maharashtra
  • 400057
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
509079BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2001
GUFICBIONSEI (National Stock Exchange of India)YesEquity SharesININRMar 2001

Biography

Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. It manufactures active pharmaceutical ingred ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 19:33
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.